HOWL

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #1 (Strong Buy) rating based on upward trends in earnings estimates. The company's consensus estimate has increased 17.6% over the past three months, positioning it in the top 5% of Zacks-covered stocks. The upgrade reflects improving business fundamentals that could drive near-term stock price appreciation.

Krystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development.

TG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027.

Mirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids.

The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million.

Zacks has added five stocks to its Strong Buy list based on positive earnings estimate revisions over the last 60 days. The stocks include Lumentum Holdings (optical/photonic products), Werewolf Therapeutics (cancer biopharmaceutical), Perion Network (digital advertising), Goldman Sachs BDC (business development), and Griffon Corporation (diversified management).